The company’s co-founders said they are leaving to start a new mRNA-based company.

The co-founders of vaccine maker BioNTech are stepping down to launch a venture focused on next-generation messenger RNA ...

Ugur Sahin and Özlem Türeci were instrumental in developing the first COVID-19 vaccine to be approved in the West. Now they ...

By Ludwig Burger FRANKFURT, March 10 (Reuters) - The two co-founders and leading executives of Germany's BioNTech will leave the COVID-19 vaccine maker by the end of 2026 to start again with a new ...

The stock was down 14% premarket after BioNTech announced the departures and issued revenue guidance that fell short of Wall Street’s forecasts.

BioNTech (BNTX) stock slides as 2026 revenue outlook misses forecasts and a CEO succession begins. Read more here ...

BioNTech’s CEO and his fellow co-founder will depart the biopharma by the end of the year to head up a new company focused on “next generation mRNA innovations.” Uğur Şahin, M.D., who is currently the ...

BioNTech SE’s founders will leave the company to start a new biotech focused on messenger RNA, the technology behind their blockbuster Covid-19 vaccine, dashing investors’ confidence in the firm’s ...

FRANKFURT, March 10 (Reuters) - The cofounders of BioNTech, Ugur Sahin and Oezlem Tuereci, will leave the COVID-19 vaccine maker by the end of 2026 to set up their own new company, the biotech firm ...

Q4 2025 earnings call: 2026 revenue guidance, COVID vaccine outlook, oncology pipeline updates, and leadership transition—read now.

Some vaccine advisers under Robert F. Kennedy Jr sought to potentially stop recommending mRNA shots, but that plan is no longer moving forward.

Now, it’s worth noting Stock Advisor’s total average return is 955 % — a market-crushing outperformance compared to 191% for the S&P 500. Don't miss the latest top 10 list, available with Stock ...